Jim Cramer on Johnson & Johnson: “J&J is Just Beginning Its Move”

Johnson & Johnson (NYSE:JNJ) is one of the stocks that Jim Cramer shed light on. Cramer was incredibly bullish on the company as he said:

“Now, sometimes in this game, you do just get lucky. You’ll come across a surprise quarter that tells you everything you need to know about what can cause a big cap stock to rally 10 points in a session. You’ll see how a star is born and even get a blueprint for what you need, what you should be looking for. Yesterday, we got a beautiful schematic from none other than Johnson & Johnson… which handed you a 10-point victory for the ages… This company put on a clinic that showed you exactly how you can orchestrate such a big gain… What does it take? Surprises, many surprises, that’s what…

… So, what did J&J have going for it?… Point blank, you got the holy quadruple. That’s J&J beating sales and earnings estimates for the quarter and then raising their sales and earnings guidance for the future… J&J raised its full-year reported sales guidance by $2 billion to midpoint, its earnings per share guidance by 25 cents. That’s just a monster set of numbers for a company whose stock has been languishing.

In the case of the pharmaceutical industry, you need to show some breakthroughs. J&J revealed some results of a 5-year trial that showed how their multiple myeloma immunotherapy is bringing a real-life-saving hope to patients suffering from this horrendous form of cancer…

J&J had previously put out some very high estimates for the cost of tariffs, and they took them down dramatically. You know what? That made me feel terrific because there are too many companies that are going to have to raise their tariff estimates, which will crush their stocks. For J&J, they cut their tariff forecast from $400 million down to 200 million. I’m calling that better than a sharp stick in the eye…

The bottom line: Check your stocks. Do they have a chance to change their stripes like J&J? Do they fit the formula? Remember, J&J is just beginning its move. Then you know what? You may be just sitting on, say it with me, a gold mine.”

Jim Cramer on Johnson & Johnson: "J&J is Just Beginning Its Move"

Trong Nguyen / Shutterstock.com

Johnson & Johnson (NYSE:JNJ) develops, manufactures, and sells healthcare products, including prescription treatments across areas such as immunology, oncology, neuroscience, and cardiovascular disease, along with medical technologies used in surgery, orthopaedics, cardiovascular care, and vision correction.

While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.